December 21, 2017
Galenicum received the approval of the DCP of Anagrelida on December 6th for several countries in Europe, including Germany, France, the Czech Republic, the Nordic countries and the UK.
The DCP was presented on November 21st, 2016 for these countries and in the coming months it is expected to obtain national [...]
December 1, 2017
This week GSI has participated in the FI Europe fair held in Frankfurt, a biannual event that brings together the largest manufacturers of food ingredients worldwide. At the show, GSI held meetings with their principals to form new commercial strategies for the next years.
In accordance with GSI’s expansion strategy, an agreement [...]
November 24, 2017
One more year, Galenicum has participated in the 8th edition of the Innovation Quest, an event created by eJuventut, an association of ESADE business school where students of BBA (Bachelor Business Administration) are challenged to solve a business case. In this edition, along with Galenicum, other seven companies and 200 students organized in [...]
November 17, 2017
The U.S. Food and Drug Administration has determined the agency will recognize eight European drug regulatory authorities as capable of conducting inspections of manufacturing facilities that meet FDA requirements. The eight regulatory authorities found to be capable are those located in: Austria, Croatia, France, Italy, Malta, Spain, Sweden [...]
November 10, 2017
Galenicum Special Ingredients (Galenicum) is partnering with Optibiotix, a life sciences company specialising in the modulation of the human microbiome, to commercialise products that will address health concerns such as high blood pressure and cholesterol.
The supply agreement provides Galenicum with a license to commercialise [...]
November 7, 2017
The pharmaceutical company headquartered in Barcelona has entered the Colombian market with the support of local partners. The firm also operates in Brazil, Chile, Peru and the Dominican Republic.
Founded in 2003 in Barcelona by Joaquim Domingo, Erich J.W. Büchen and Alejandro Ollé —the company’s only [...]
November 3, 2017
Once again, Galenicum Health and Galenicum Special Ingredients (GSI) attended the CPhI Worldwide event, which took place in Frankfurt from 24-26th October. CPhI is the world’s largest pharma trade show.
During the exhibition, we had the opportunity to present Galenicum’s new portfolio including a variety of new developments [...]
October 19, 2017
On 19 October every year, the International Day against Breast Cancer is held as a reminder about the commitment to the fight against breast cancer.
Breast cancer is the most common malignant tumor among women worldwide, (with the exception of non-melanoma cancerous tumors of the [...]
October 10, 2017
October 10th 2017 marks an anniversary: We come together to celebrate World Mental Health Day for the 25th time! World Federation for Mental Health founded the awareness day in 1992 and since then people all over the world are holding events, making announcements and celebrating #WorldMentalHealthDay.
“Mental Health in the [...]
September 28, 2017
Galenicum Special Ingredients (GSI) is the division of Galencium Health responsible for offering solutions of the highest quality in the food, nutraceutical and cosmetic industry. As part of the company’s growth strategy, and in line with its commitment to internationalization, GSI has strengthened its presence in the United States since [...]
September 21, 2017
The World Health Organization (WHO) and the International Alzheimer's Federation chose September 21 as the yearly World Alzheimer's Day in 2012.
September 7, 2017
Galenicum Health Peru has launched Caspofungin and Tigecycline. These two products mark the start of a new unit of anti-infective products for intensive care.
Tigecycline 50 mg lyophilized powder for solution for perfusion is an antibacterial in the tetracycline group for systemic use. Tigecycline is indicated for the treatment of [...]
August 28, 2017
Galenicum launched its new product, Dutasteride, in the European market in July.
Dutasteride is used for treating moderate and severe symptoms of benign prostatic hyperplasia (BPH) in men. The patent for this product expired on July 18 in most European countries.
Galenicum has reached commercial agreements with companies from [...]
August 2, 2017
World Hepatitis Day took place on 28 July, providing an opportunity to promote all the initiatives aimed at implementing the first Global health sector strategy on viral hepatitis 2016-2021, and to assist Member States in achieving the ultimate goal of eliminating hepatitis.
The WHO will support the "Eliminate Hepatitis" campaign by [...]
July 24, 2017
Galenicum completed successfully the European phase of the DCP for Tigecycline at the end of June and has already received the first national marketing [...]
July 14, 2017
Galenicum Special Ingredients is launching a new line of food supplements in the Spanish market: STOP&GO. After over a year of marketing the products in the Middle East and with positive results, the food division of Galenicum has decided to take a step further and launch them in the Spanish national [...]
January 19, 2017
On January 11, Antonio Luján, General Manager of Galenicum Peru, gave an extensive interview on Radio Capital on the program led by renowned journalist Monica Delta.
During the interview, key issues related to the Peruvian pharmaceutical sector were discussed, such as [...]
January 3, 2017
The first injectable product in Galenicum’s portfolio has been approved. The systemically-administered antifungal product is indicated for the treatment of candidiasis and invasive aspergillosis. The use of this product is restricted to severe cases due to the high cost of each vial. Galenicum is aiming to make [...]
November 24, 2016
Galenicum launches its activity in the Dominican Republic with the distributor SUED & FARGESA. The two companies have joined forces to provide suitable alternative therapies to the pharmaceutical market, contributing to better quality of life and guaranteeing that health professionals have access to high-quality [...]
October 14, 2016
Galenicum Health and Galenicum Special Ingredients (GSI) attended CPhI Worldwide this year in Barcelona from October 4-6 as they do every year. The companies' stand was visited by professionals from across entire pharmaceutical sector who were very interested in the product pipeline.
September 20, 2016
On the 30th of November last year, Sant Joan de Déu Hospital and Galenicum presented the “Hospital without Pain” in minor procedures project. The ground-breaking project in Spain seeks to minimise the pain for the youngest patients as they [...]
July 22, 2016
On Thursday, July 14 in the Axa Auditorium in Barcelona, the XXI edition of the "Acció" Investment Forum took place. Acció is the main meeting point for entrepreneurs and investors in Catalonia.
Galenicum, the pharmaceutical company founded in 2003 in [...]
July 13, 2016
Victor has an autism spectrum disorder. Every time he needs a blood test, he thinks he’s being attacked and 5 nurses are required to hold him down to perform the blood test.
Cristina wanted to share her experience with the Hospital without Pain project:
June 14, 2016
Every year, on 14th of June, countries around the world celebrate World Blood Donor Day. The event serves to thank voluntary, unpaid blood donors for their life-saving gifts of blood and to raise awareness of the need for regular blood donations to ensure the quality, safety and availability of blood and blood [...]
June 7, 2016
Last May, SAG manufacturing, a company of Galenicum Health group, received the certification from The National Health Surveillance Agency of Brazil (ANVISA) for the non-sterile solid and coated tablets plant. This certification represents a step forward in the process of entry into the Brazilian [...]
May 26, 2016
Last 24th of May, Galenicum Health Chile organized the 3rd Workshop entitled “ The proper management of the different treatments of Alzheimer disease”, which was presented by the prestigious Dr. Rodrigo Azócar O.Kuljiš. Dr. [...]
May 3, 2016
From April, 29th to May, 1st, Galenicum Health Peru participated in the XVIII Cardiology Course for the prescriber. The event was organized by the Peruvian Cardiology Society and it is the most important academic event that this Society organizes. The event was held at the ICA Dunas hotel and 250 cardiologists took [...]
April 28, 2016
One of the current problems that Peru is facing is the amount of medicines that are commercialized without bioequivalent studies. Therefore, the population is exposed to products which efficacy and safety is not guaranteed.
Bioequivalence guarantees safety and efficacy [...]
April 7, 2016
Every 7th of April the WHO celebrates the World Health Day in order to celebrate the foundation of the organization in 1948. This year the focus is to beat the diabetes. According to the World Health Organization in 2030 the diabetes will be the 7th cause of death in the world.
Diabetes is a [...]
March 11, 2016
The third edition of University Joins Industry was a success. It took place the 9th of March at the Faculty of Pharmacy of the University of Barcelona and was organized by Galenicum Health.
The workshop attracted 200 students and they had the opportunity to understand from [...]
March 7, 2016
One more year Galenicum Health, is in the Ranking of Spanish companies that have submitted more patents in the European Patent Office, having filled 12 patents. Galenicum appears in the ranking together with well-known companies such as Telefonica, Repsol, or Almirall Laboratorios Esteve.
February 23, 2016
In recent decades, biotechnology has allowed the development of more than 650 biological innovative drugs to treat diseases like cancer and other serious diseases, such as haematological, neurological or endocrine illnesses. In the coming years a high percentage of drugs to be launched are going to be biological in [...]
January 25, 2016
January the 20th, la Vanguardia, a Spanish renowned newspaper, mentioned Galenicum as one of the most relevant players in the Spanish generic market. Galenicum as well as other important generic companies contribute in generating wealth in the market as well as stable employment.
The pharmaceutical generic sector in Spain is [...]
January 11, 2016
El Comercio, one of the most renown Peruvian newspapers, echoed recently on the relevant steps done during 2015 of the Peruvian Galenicum Health subsidiary.
Galenicum Health Peru was the first and is still the only pharmaceutical company with all portfolio products with a bioequivalence certificate. This fact has been key for [...]
December 1, 2015
Galenicum collaborates with Hospital Sant Joan de Déu, a referent hospital in Barcelona and Spain, in order to protect the most vulnerable patients, children.
On November 30th the Hospital presented the programme “Hospital without pain” in minor [...]
November 23, 2015
Galenicum and 7 other companies, Vodafone, ISS, Zurich, La Caixa, Zodiac and Human Age Institute, participated in the sixth edition of Innovation Quest, an event created by eJuventut, an association of ESADE Business School. In this edition, 200 students from different years participated.
November 13, 2015
Galenicum participated the last 4 [...]
October 23, 2015
Galenicum Health and Galenicum Special Ingredients (GSI) recently exhibited at the 2015 CPhI Worldwide. It was a fantastic opportunity to present new developments and to connect with other companies. Wednesday, Galenicum organized their renown annual cocktail, inviting its partners and colleagues from the [...]
September 4, 2015
According to an article at Expansion newspaper on the last 28th of August, the pharmaceutical industry is booming again after years of stagnation thanks to the increase on the sales of generic drugs. Generics in Spain have doubled their sales from 2010 to 2014.
August 7, 2015
In Europe and United States generic drugs are supported by bioequivalence studies that ensure their efficacy and security. Unfortunately, the situation is different in some Latin [...]
July 29, 2015
The importance of Bioequivalent Drugs was highlighted by the President of the Republic of Peru on his traditional annual speech on the Independence day as one the main messages to the population.
Yesterday 28th of July, Independence Day in Peru, Ollanta Humala announced that Peru will perform this year Bioequivalence [...]
July 24, 2015
Generic medicines are highly accepted by the population in many countries of the European Union. In countries such as Germany and UK the rate of generic drugs exceeds the 60% over the total consumed drugs.
Even though, there is still a lot to be done in order to overcome the myths that surrounded the generic drugs:
July 20, 2015
The generics pharmaceutical industry is going through a change based on differentiation. Up to now, the generics industry has been based only on the price as the main business variable. However, this is changing, and the last speech of Herman Grohe, Germany Health Minister, at the European Generics Association (EGA) [...]
July 10, 2015
Galenicum launches a video taking advantage of GalenicumVitae, the new Health Guide. The objective is to link graphic and didactically the products with the associate pathology.
July 3, 2015
The pharmaceutical company Galenicum in collaboration with Parc Sanitari Sant Joan de Déu, a Spanish prestigious medical institution, has developed a complete and innovative online health Guide which satisfies an unmet need up to now: to make available to everybody a source of easy and understandable [...]
June 19, 2015
Galenicum Special Ingredients takes a step ahead and expands the product portfolio in new categories like fibres, sugars, sweeteners and functional products that will fulfill specific needs of each client.
With this new commercial initiative, GSI expects to increase their [...]
The Peruvian Doctors Association reflects the need of implementing the bioequivalence studies as a measure of safety and effectiveness of generic drugs
June 2, 2015
Nowadays, in Peru, pharmacies have mostly original drugs and therefore the pharmaceutical expenses are high. This is the reason why the promotion of generic drugs is crucial. Unfortunately, it is still not mandatory to ensure by bioequivalence studies that the generic drugs are as safety and effective as the original ones.
May 26, 2015
Two journalists from the well-recognized Peruvian TV show Día D, (Canal 9) travelled to Spain in order to shoot a documentary about the concept of bioequivalence and the situation of generic drugs in Spain.
In Peru, the pharmaceutical industry is developing [...]
May 4, 2015
In this interview Agustín Ossandón, General Manager of Galenicum Chile, explains the characteristics of generic bioequivalent medicines, which guarantee the same therapeutic effectiveness, absorption and safety as original medicines. In turn, he presents an analysis of the situation of the Chilean market, which is experiencing an [...]
April 23, 2015
Antonio Luján, General Manager of Galenicum Perú, was interviewed on “Mundo Empresarial”, Canal N’s business news program presented by Bruno Giuffra. The interview included a discussion of the current situation of [...]
March 23, 2015
Galenicum was one of the many companies participating in the 25th edition of the Forum ETSEIB, a benchmark event at a European level organized annually by the School of Industrial Engineering of Barcelona, belonging to the Universitat Politècnica de Catalunya (UPC).
March 18, 2015
Galenicum and the Universitat de Barcelona (UB) Faculty of Pharmacy have collaborated in the second edition of “University Joins Industry”, a training workshop designed to raise awareness among students of the various opportunities available in all areas of the pharmaceutical industry. The seminar was organized by the Faculty of [...]
March 11, 2015
The European Patent Office (EPO) has published the ranking of patent applications submitted during the 2014 fiscal year in Europe. The pharmaceutical company Galenicum, with 21 applications, is now in the second company in the sector and the fifth at a national level. This is the result of a significant boost in recent years in the area of [...]
February 24, 2015
The introduction onto the Peruvian market of the first bioequivalent drugs made by Galenicum has attracted large media coverage in Peru. Galenicum is one of the first companies to provide this type of drug, in advance of the Directive pending approval that will establish the bioequivalent requirements, as in the case of other South American [...]
February 12, 2015
Xavier Trias, Mayor of Barcelona, and Cristina Iniesta, Health Representative of the Barcelona City Council, visited the Galenicum headquarters to celebrate the Business of the Year prize awarded to the company in the latest edition of the European Business Awards. These awards recognize the most innovative businesses on the European continent [...]
Galenicum, guest of honor at the Spain National Champions reception of the European Business Awards 2014/15
January 30, 2015
Alejandro Ollé, founding member of Galenicum, was guest of honor at the reception offered to the Spain National Champions of the prestigious European Business Awards 2014/15, held in Hotel Hesperia Presidente in Barcelona. During the ceremony, thirty two awards were presented to the Spanish companies selected in this edition. These [...]
October 16, 2014
Galenicum has completed the tigecycline development process, a broad-spectrum antibiotic in the tetracycline family, with a suitable efficacy and safety profile to treat complicated [...]
October 9, 2014
Galenicum was one of the exhibiting companies at CPhI Worldwide 2014 in Paris, the leading event in the generic drug industry, where we presented the new developments in our products portfolio and introduced our new manufacturing installations.
Last night, we held our traditional cocktail party, which was attended by a large number of [...]
September 29, 2014
For the second consecutive year, Galenicum has participated in the fifth edition of the ESADE Innovation Quest in Barcelona, a four-day event organised by the business school, which consists on a case competition between BBA, Law, Engineering and MSc Students who should propose innovative solutions to real cases of the participant companies. [...]
June 2, 2014
May 19, 2014
In December 2013 Galenicum obtained the approval of CODEM, the Spanish Drug Evaluation Committee, for almotriptan, and began the process for authorizing its sale once the patent is finalized. The main use of Almotriptan, a drug from the family of selective serotonin receptor agonists, is the treatment of migraine symptoms.
March 20, 2014
On the 11th and 13th of March, Galenicum took part in the 24th edition of the ETSEIB Forum organized by the Industrial Engineering School of Barcelona, which had the participation of numerous leading companies at both the national and international levels, and which has consolidated itself as one of the European forums of reference in its [...]
January 24, 2014
Galenicum has teamed up with fellow Spanish company Uriach to introduce cilostazol 100mg tablets in Sweden and the UK through local distributors. The two firms, which partnered on development and manufacturing, also plan to launch their rival to Otsuka’s Pletal treatment for intermittent claudication through third parties in countries [...]
January 15, 2014
The European Business Awards (EBA) has announced that Galenicum has been honoured with a Ruban d’Honneur in the 2013/14 edition of these prestigious continental awards. Shortlisted as one of the ten runners up in the category of Infosys Business of the Year Award (turnover €26-150m), Galenicum will go through to the third and [...]
December 5, 2013
Sant Joan de Déu Barcelona Children’s Hospital is working on a pioneering initiative called the ‘Hospital Without Pain’, a pilot project created and executed by the healthcare institution, in which a group of professionals is working on implementing a series of measures geared towards minimising the pain and discomfort [...]
November 20, 2013
During the months of October and November 2013 Galenicum has implemented an initiative in the Faculty of Pharmacy at the University of Barcelona. Forming part of the social commitment of the company and designed for training future professionals, the University Joins Industry workshops have provided participants with the opportunity to obtain a [...]
October 24, 2013
After two intense days of work at the world's largest event of the generic industry, where we presented the new developments in the Galenicum's product portfolio, last night we celebrated our [...]
October 7, 2013
The fourth edition of the ESADE Innovation Quest closed in Barcelona on 30 September. This four-day event organised by eJoventut, a junior consultancy association managed by ESADE Business & Law School students, was centred on the search for innovative solutions for practical cases presented by five companies from various sectors. More than [...]
July 17, 2013
The European Business Awards (EBA) announced that Galenicum had been selected as one of the National Champions to represent Spain in the 2013/14 edition of these prestigious awards. This means that Galenicum is considered to be one of the 526 National Champions selected from among companies from 31 European countries, and Spain will have 40 [...]
July 4, 2013
At Galenicum we have recently presented our Innovation Awards, an in-house acknowledgement given to the most innovative ideas presented on a specific topic. The entire staff is divided into a series of work teams comprising members of different company departments and invited to take part. The aim of this yearly initiative is to promote [...]
June 4, 2013
Galenicum has submitted the dossier for Almotriptan 12.5 mg film-coated tablets in May 2013 in Portugal, Spain, France, Italy and United Kingdom, following the submissions for Dutasteride and Cilostazol over the past months. The drug is used in the treatment of heavy migraine headache, and prescribed to treat the acute headache phase of the [...]
April 8, 2013
Galenicum has received on March 2013 the Marketing Authorizations in Spain for Dexketoprofen 25 mg sachets (granulate), a non-steroidal anti-inflammatory drug indicated for short-term treatment of mild to moderate pain, including dysmenorrhoea. In addition, the company will submit Dexketoprofen 25 mg oral solution in sachets in May 2013 in [...]
March 29, 2013
Vouching for talent is still a major driving force of growth at Galenicum, the most valued asset in its internationalisation strategy, and hence throughout last year and the first quarter of 2013 the company has made a series of new recruitments with a view to strengthening practically all of its departments.
Expanding the human team [...]
February 26, 2013
Galenicum Health Peru and Laboratorios Rubió have signed an exclusive distribution agreement for Rubifen, to serve both private and institutional markets in the Andean country. The drug is used to treat attention deficit disorder with hyperactivity (ADHD) in adolescents and children aged 6 and older, in which other non-pharmaceutical [...]
January 15, 2013
Galenicum has opened new offices in Lima as a new step in its international expansion through the American continent, applying the innovative and successful model implemented by the company in Europe. The project will be led by Antonio Luján as General Manager, a professional with over 10 years of experience in the pharmaceutical [...]
December 27, 2012
Galenicum has confirmed that Dutasteride 0.5 mg soft gel capsules used for the treatment of benign prostatic hyperplasia (BPH) have been given proof of bioequivalence to the commercialized Avodart 0.5 mg capsules. The registration is expected to start by January 2013.
It is the latest generic drug developed by Galenicum to successfully [...]
October 11, 2012
Last evening we lived one of the most enjoyable moments during the celebration of our traditional cocktail at CPhI Worldwide 2012, attended by a large number of industry professionals who decided to join us. We had a wonderful time chatting and sharing some snacks and drinks after two days of hard work, so we would like to thank all the [...]
October 9, 2012
Today begins a new edition of CPhI Wordwide, one of the leading events of the global pharmaceutical industry, with near 30,000 attendees from over 133 countries. At Galenicum we are willing to share with you our recent product developments and our new corporate image, so you are invited to believe in life and visit us at booth 5F23, Hall [...]
August 27, 2012
Galenicum has opened new offices in São Paulo and is thus launching operations in the American continent. Galenicum Brazil will apply the innovative model implemented by the company in Europe through a team of local professionals, who will offer a service adapted to local requirements in order to handle the specific needs of [...]
June 29, 2012
Galenicum is pleased to announce the composition of its Strategy Board, whose members are advising the company on the development of the new Strategic Plan that will draw the guidelines of our international expansion.
Arun Sawhney An industry veteran with over three decades of international experience in the Chemical [...]
March 1, 2012
Galenicum attended the EuroPLX 45 that took place from 28th February to 1st March 2012 in Cascais, Portugal. EuroPLX, a leading partnering event for pharma and biopharma business development, was attended by delegates of more than 150 pharmaceutical companies from 34 countries around the world. Our presence in the event was a great [...]
November 4, 2011
We are glad to communicate to all our clients and partners, that Galenicum has successfully passed the inspection of the Extension of the QcLAB performed by the AGEMED (Agencia Española del Medicamento) and that gives the GMP [...]
November 2, 2011
Galenicum would like to thank its clients and partners, for the attendance to our CPHI booth, and in particular to the cocktail of October 26th,where we had a very good time together. Galenicum evaluates the outcome of the fair as very positive, since we have been able to advance in several development projects that will increase our [...]
October 14, 2011
Galenicum has upgraded its quality control lab, doubling the surface of its existing Lab in Esplugues, Barcelona.The new investment will significantly increase the batch release capacity with the aim of improving lab lead times [...]